VAXIPET DHPP+L LYOPHILSATE FOR INJECTION (FOR DHPPT FRACTION: VIRUS FEBRIS CONTAGISSAE CANIS STRAIN, VIRUS LARYNGOTRACHETIDIS CONTAGIOSAE CANIS STRAIN PARAOVIRUS ENTERITIDIAS CANIS, VIRUS PARAINFLUENCES CANIS STRAIN, LEPTOSPIRA ICTEROHAEMORRHAGISE INACTIVATED, LEPTOSPIRA CANICOLA INACTIVATED AND LEPTOSPIRA GRIPPOTYPHOA INACTIVATED)

Indications

• Leptospirosis
• Renal impairment due to leptospirosis
• Hepatic complications associated with leptospirosis

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidance, as no specific dosing is provided.

Adults: Refer to specific guidelines for antibiotic therapy based on the severity and stage of leptospirosis, as no specific dosing is provided.

Mechanism of action

Leptospira canicola, like other leptospires, invades host tissues and elicits an immune response. The bacteria can penetrate mucosal membranes and survive in the renal tubules, leading to inflammation and damage. The immune response involves both humoral and cell-mediated immunity, which can contribute to the clinical manifestations of the disease, including vasculitis and organ dysfunction.

Pharmacodynamics

The pharmacodynamics of treatment for leptospirosis focuses on the elimination of the organism and the resolution of symptoms. Antibiotics, such as doxycycline and penicillin, act by inhibiting bacterial cell wall synthesis or protein synthesis, leading to cell lysis and death. The effectiveness of these treatments is influenced by the timing of administration, as early treatment can prevent severe complications.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis, such as doxycycline, include rapid absorption from the gastrointestinal tract, high bioavailability, and extensive tissue distribution. Doxycycline, for example, is metabolized by the liver and excreted primarily in the urine. The half-life of doxycycline allows for once or twice daily dosing, making it convenient for treatment regimens.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether canicola is excreted in human milk. Caution should be exercised when administered to a nursing woman.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Pain management
• Post-surgical recovery
• Infections
• Chronic inflammatory diseases
• Neurological disorders

Dosage

Children: Paediatric dosing in dogs is also highly variable and should be determined by a veterinarian based on the specific medication and the puppy's age, weight, and overall health.

Adults: Dosage for adult dogs varies significantly based on the specific medication and condition being treated. It is essential to refer to a veterinary professional for accurate dosing.

Mechanism of action

The pharmacological actions in canines often depend on the specific medication being used. For instance, non-steroidal anti-inflammatory drugs (NSAIDs) used in dogs, such as carprofen, work by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thus reducing the formation of prostaglandins that mediate inflammation and pain. Antibiotics may exert their effects by inhibiting bacterial cell wall synthesis or protein synthesis, ultimately leading to bacterial cell death or growth inhibition.

Pharmacodynamics

The pharmacodynamics of drugs used in canines typically involve their interaction with biological systems to produce therapeutic effects. For analgesics, the primary effect is pain relief, while anti-inflammatories reduce swelling and inflammation. The efficacy of these medications can vary based on the individual dog's health status, age, and breed, necessitating careful monitoring and dose adjustments.

Pharmacokinetics

Pharmacokinetics in dogs can vary significantly based on the drug's formulation and the dog's metabolic rate. Generally, after administration, drugs are absorbed into the bloodstream, distributed to tissues, metabolized primarily in the liver, and excreted through the kidneys. Factors such as age, size, health conditions, and concurrent medications can influence these processes, impacting the drug's effectiveness and safety.

Pregnancy

Safety during pregnancy has not been established. Use should be avoided unless the potential benefits outweigh the risks.

Breast-feeding

Safety during breastfeeding has not been established. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Indications

• Viral infections
• Bacterial infections
• Parasitic infections
• Fungal infections
• Contagious diseases like influenza, chickenpox, and tuberculosis

Dosage

Children: Refer to paediatric dosing guidelines based on the specific infectious agent and clinical context.

Adults: Refer to specific treatment guidelines based on the infectious agent and clinical context.

Mechanism of action

The mechanism of action for contagiosae can vary widely depending on the specific pathogen and the host's immune response. Generally, infectious agents invade host cells, reproduce, and cause cellular damage, leading to symptoms of disease. The immune system responds by activating various pathways, including the innate and adaptive immune responses, to eliminate the pathogen.

Pharmacodynamics

Pharmacodynamics in the context of contagiosae involves understanding how the body responds to the infectious agent and the medications used for treatment. This includes the interaction between the drug and the pathogen, the immune response elicited by the infection, and the resultant effects on the host's physiology. Medications may work by inhibiting pathogen replication, enhancing immune responses, or alleviating symptoms.

Pharmacokinetics

Pharmacokinetics for treatments related to contagiosae includes absorption, distribution, metabolism, and excretion of the drugs used. Absorption may be affected by the route of administration, with some drugs administered orally, intravenously, or topically depending on the infection's location. Distribution involves the drug's reach to tissues and fluids where the pathogen resides. Metabolism typically occurs in the liver, and excretion may primarily happen through the kidneys. These factors influence the drug's efficacy and safety.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether contagiosae is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Dosage

Children: Refer to the appropriate clinical guidelines or consult a healthcare professional for dosing information.

Adults: Refer to the appropriate clinical guidelines or consult a healthcare professional for dosing information.

Mechanism of action

Unknown. Without specific pharmacological data, the mechanism of action for contagissae cannot be determined.

Pharmacodynamics

Unknown. There is no available information regarding the pharmacodynamics of contagissae in terms of its effects on the body, including therapeutic and adverse effects.

Pharmacokinetics

Unknown. The pharmacokinetic profile, including absorption, distribution, metabolism, and excretion of contagissae, has not been established in available literature.

Pregnancy

There is limited data on the safety of contagissae during pregnancy. It is advisable to use caution and consult a healthcare professional before use.

Breast-feeding

The excretion of contagissae in human milk is unknown. Caution is recommended when administering to breastfeeding women.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Foodborne infections
• Gastroenteritis
• Salmonellosis
• Bacterial enteritis

Dosage

Children: Paediatric dosing depends on the specific antibiotic prescribed and the child's weight and age. Refer to the BNF for Children for accurate dosing information.

Adults: Dosage varies based on the specific antibiotic used and the severity of the infection. Refer to relevant clinical guidelines for appropriate dosing.

Mechanism of action

The mechanism of action for antibiotics used to treat infections caused by Enterobacteriaceae typically involves inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, leading to bacterial cell death or growth inhibition. Common classes of antibiotics include beta-lactams, aminoglycosides, and fluoroquinolones, each targeting specific bacterial processes.

Pharmacodynamics

Pharmacodynamics refers to the effects of drugs on the body, particularly the relationship between drug concentration and effect. Antibiotics generally exhibit time-dependent or concentration-dependent killing. For example, beta-lactams are time-dependent, meaning their efficacy is related to the duration of time the drug concentration remains above the minimum inhibitory concentration (MIC) for the target bacteria.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion of drugs. Antibiotics are typically absorbed in the gastrointestinal tract, distributed throughout body tissues and fluids, metabolized by the liver, and eliminated via the kidneys. The specific pharmacokinetics can vary significantly between different classes of antibiotics used against Enterobacteriaceae.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and the benefits outweigh risks.

Breast-feeding

Caution is advised. Consult a healthcare provider before use.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Fever
• Mild to moderate pain
• Headache
• Muscle aches
• Arthritis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Febris primarily acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are mediators of inflammation and fever. By reducing the levels of these compounds, febris leads to decreased hypothalamic set-point, thereby lowering body temperature.

Pharmacodynamics

The pharmacodynamic effects of febris include its analgesic, antipyretic, and anti-inflammatory properties. It effectively reduces fever in response to infection or inflammation by acting on the hypothalamus. It also provides pain relief by inhibiting prostaglandin synthesis, thus alleviating symptoms associated with various conditions such as headaches, muscle aches, and arthritis.

Pharmacokinetics

Febris is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours following oral administration. It is metabolized primarily in the liver, undergoing conjugation to form inactive metabolites. The elimination half-life varies between individuals but is generally around 2-4 hours. The drug is excreted primarily through the kidneys, with a small amount eliminated in feces.

Pregnancy

Use with caution, as safety during pregnancy has not been established.

Breast-feeding

Use with caution, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Prevention of typhoid fever
• Prevention in individuals traveling to endemic areas
• Vaccination in populations at high risk of exposure

Dosage

Children: Refer to the specific product guidelines and local recommendations for dosing.

Adults: Refer to the specific product guidelines and local recommendations for dosing.

Mechanism of action

Grippotyphoa induces an immune response by introducing inactivated or attenuated strains of the bacteria that cause typhoid fever. This exposure prompts the body to produce antibodies and activate T-cells, which will recognize and combat the actual pathogenic bacteria if the person is exposed in the future. The immune memory created by the vaccine significantly reduces the risk of developing typhoid fever.

Pharmacodynamics

The pharmacodynamics of Grippotyphoa involve the activation of the immune system, particularly the humoral immune response. Following administration, the vaccine stimulates the production of specific antibodies against the bacterial antigens. This process enhances the body's ability to recognize and fight off the bacteria upon subsequent exposure, leading to an increased level of protection against typhoid fever and associated infections.

Pharmacokinetics

The pharmacokinetics of Grippotyphoa are characterized by its administration route, which is typically through injection. The vaccine components are processed by the immune system, with antibodies being produced over a period of days to weeks. The duration of immunity can vary, but booster doses may be required to maintain adequate protection against typhoid fever. The metabolism and excretion of the vaccine components depend on the body's immune response rather than traditional drug metabolism pathways.

Pregnancy

Consult a healthcare provider before use, as safety in pregnancy has not been established.

Breast-feeding

Consult a healthcare provider before use, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

Dosage

Children: Refer to clinical guidelines or relevant pharmacological references for specific dosing information.

Adults: Refer to clinical guidelines or relevant pharmacological references for specific dosing information.

Pregnancy

The safety of icterohaemorrhagise in pregnancy has not been established. Use only if the potential benefit justifies the risk to the fetus.

Breast-feeding

It is not known whether icterohaemorrhagise is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific manufacturer guidelines for storage.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Laryngotracheitis
• Croup
• Acute upper airway obstruction
• Viral respiratory infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing in paediatric patients, as doses will depend on the child's age and weight.

Adults: Refer to specific guidelines or the BNF for appropriate corticosteroid dosing for adults, as it varies based on severity and specific medication used.

Mechanism of action

The primary mechanism of action for corticosteroids, commonly used in treating laryngotracheitis, involves the inhibition of inflammatory pathways, leading to decreased airway inflammation and edema. They act by binding to glucocorticoid receptors, which modulate the transcription of various genes involved in the inflammatory response.

Pharmacodynamics

Corticosteroids exert multiple effects on the immune system and inflammatory processes. They inhibit the migration of leukocytes and the release of inflammatory mediators, leading to reduced swelling and mucus production in the airways. This results in improved airflow and relief of symptoms associated with laryngotracheitis.

Pharmacokinetics

Corticosteroids are rapidly absorbed following oral administration, with peak plasma concentrations typically occurring within 1 to 2 hours. They have a high volume of distribution and are extensively bound to plasma proteins. Metabolism occurs primarily in the liver, and the excretion is mainly via urine. The half-life varies depending on the specific corticosteroid used.

Pregnancy

There are no well-controlled studies in pregnant women. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Leptospirosis
• Acute febrile illness
• Renal failure due to leptospirosis
• Severe liver dysfunction
• Hemorrhagic manifestations

Dosage

Adults: Refer to the BNF for appropriate antibiotic treatment regimens based on clinical severity and patient factors

Mechanism of action

Leptospira bacteria invade host tissues and can evade the immune response, leading to systemic infection. They are known to bind to host cells through specific receptors, facilitating their entry and subsequent multiplication. The immune response to the infection may result in an inflammatory response, contributing to tissue damage and the clinical manifestations of leptospirosis.

Pharmacodynamics

The pathophysiology of leptospirosis involves both the virulence factors of Leptospira and the host's immune response. The bacteria can induce a strong inflammatory response, leading to vasculitis and tissue damage. Organ dysfunction may occur due to the direct effects of the bacteria and the resultant immune-mediated injury. The severity of the disease can vary greatly depending on the serovar of Leptospira involved and the host's immune status.

Pharmacokinetics

Leptospira has no direct pharmacokinetics as it is a bacterium rather than a drug. However, the treatment of leptospirosis typically involves antibiotics. Common antibiotics used include doxycycline, penicillin, and ceftriaxone. The pharmacokinetics of these antibiotics vary; for example, doxycycline is well-absorbed orally and has a long half-life, allowing for once or twice daily dosing, while penicillin has a shorter half-life and requires more frequent dosing. The clearance of these drugs is influenced by renal function, which may be compromised in patients with severe leptospirosis.

Adverse effects

• Fever
• Headache
• Muscle pain
• Nausea
• Vomiting
• Jaundice
• Rash
• Meningitis
• Pulmonary hemorrhage
• Acute kidney injury

Precautions

• Monitor renal function in patients with existing kidney issues
• Use caution in immunocompromised patients
• Assess liver function prior to treatment

Pregnancy

The safety of leptospira treatment during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not well studied in breastfeeding women. Caution is advised.

Storage

Store at room temperature, away from direct sunlight. Keep out of reach of children.

Indications

• Croup
• Bronchitis
• Pneumonia
• Upper respiratory tract infections

Dosage

Children: No

Adults: No specific dosage is available for adults as treatment primarily focuses on supportive care and management of symptoms.

Mechanism of action

Parainfluenza viruses infect respiratory epithelial cells, leading to cell injury and inflammation. The viral replication process involves the attachment of the virus to specific receptors on the host cell, followed by fusion of the viral envelope with the host cell membrane. This allows the viral RNA to enter the host cell and hijack the cellular machinery to produce viral proteins and replicate the viral genome. The resulting viral progeny are released, leading to the spread of infection and resultant respiratory symptoms.

Pharmacodynamics

The primary pharmacodynamic effect of parainfluenza virus infections is the induction of an inflammatory response in the respiratory tract. This can cause symptoms such as cough, wheezing, and difficulty breathing due to airway obstruction and inflammation. In severe cases, especially in young children, this can lead to significant respiratory distress and may require hospitalization. The immune response to infection includes both innate and adaptive mechanisms, contributing to the clearance of the virus, but also resulting in tissue damage and symptoms.

Pharmacokinetics

As a viral pathogen, parainfluenza viruses do not have classical pharmacokinetics like drugs. However, understanding the kinetics of viral replication is important. After initial infection, the virus begins to replicate rapidly within the host cells over a period of hours to days. The viral load in respiratory secretions typically peaks within the first week of illness. The immune response eventually leads to the clearance of the virus, although some strains can persist longer in immunocompromised individuals.

Pregnancy

There is limited information regarding the safety of parainfluenza viruses during pregnancy. Consultation with a healthcare professional is advised.

Breast-feeding

The safety of parainfluenza viruses during breastfeeding is not well established. Consultation with a healthcare professional is recommended.

Storage

Parainfluenza viruses are typically stored according to laboratory guidelines for viral cultures. Specific storage conditions may vary depending on the formulation.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Congenital infection in pregnant women

Dosage

Children: There are no specific antiviral treatments available for parvovirus infections in children; management is symptomatic and supportive.

Adults: There are no specific antiviral treatments available for parvovirus infections in adults; management is symptomatic and supportive.

Mechanism of action

Parvovirus B19 specifically targets erythroid progenitor cells in the bone marrow, leading to a disruption in erythropoiesis. The virus attaches to the P antigen on the surface of these progenitor cells, facilitating its entry and subsequent replication. This process results in cell lysis and a decrease in red blood cell production, which can lead to anemia in susceptible individuals.

Pharmacodynamics

The pharmacodynamics of parvovirus treatment focuses on managing symptoms and preventing complications rather than the direct antiviral treatment, as no specific antiviral agents are available for parvoviral infections. Supportive care is emphasized, which may include hydration, pain relief, and blood transfusions in cases of severe anemia.

Pharmacokinetics

Parvovirus B19 has a relatively short incubation period of approximately 4 to 14 days. The virus can be detected in the blood during the acute phase of infection, typically before the onset of symptoms. The immune response, particularly the production of IgM and IgG antibodies, leads to viral clearance, with most patients recovering within a few weeks. In immunocompromised patients, the virus may persist longer, requiring monitoring and supportive care.

Pregnancy

There is limited data on the effects of paraovirus during pregnancy. Caution is advised, and pregnant individuals should consult a healthcare provider before exposure.

Breast-feeding

Limited data is available regarding the excretion of paraovirus in breast milk. Caution is recommended when administering to breastfeeding individuals.

Storage

Store in a cool, dry place, away from direct sunlight. Follow specific storage instructions if available.

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.